Immunochemical analysis of human papillomavirus L1 capsid protein in liquid-based cytology samples from cervical lesions

Acta Cytologica

Volumn 54, Issue 5, 2010, Pages 661-667

  Xiao, Wei ^a   Bian, Meilu ^a   Ma, Li ^a   Liu, Jun ^a   Chen, Ying ^a   Yang, Bin ^b   Wu, Qingze ^c  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

Cervical intraepithelial neoplasia; Human papillomavirus; L1 capsid protein; Liquid based cytology

Indexed keywords

CAPSID PROTEIN L1; CAPSID PROTEIN; HPV L1 PROTEIN, HUMAN PAPILLOMAVIRUS; ONCOPROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CYTODIAGNOSIS; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UTERINE CERVICITIS; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; ALPHAPAPILLOMAVIRUS; ENZYME IMMUNOASSAY; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; PRECANCER; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR; VIROLOGY;

HUMAN PAPILLOMAVIRUS; MIRIDAE;

ADULT; AGED; ALPHAPAPILLOMAVIRUS; CAPSID PROTEINS; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTODIAGNOSIS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 78149233037     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000325229     Document Type: Article

References (26)

1. Bosch FX, Munoz N: The viral etiology of cervical cancer. Virus Res 2002;89:183-189
2. Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E, Wadell G: Human papillomavirus infection is transient in young women: A population-based cohort study. J Infect Dis 1995;171:1026-1030
3. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, Schiffman M: Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-474
4. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428
5. Abadi MA, Ho GY, Burk RD, Romney SL, Kadish AS: Stringent criteria for histological diagnosis of koilocytosis fail to eliminate overdiagnosis of human papillomavirus infection and cervical intraepithelial neoplasia grade 1. Human Pathol 1998;29:54-59
6. de Gruijl TD, Bontkes HJ, Walboomers JM, Coursaget P, Stukart MJ, Dupuy C, Kueter E, Verheijen RH, Helmerhorst TJ, Duggan-Keen MF, Stern PL, Meijer CJ, Scheper RJ: Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia: I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome. J Gen Virol 1999;80:399-408
7. Bontkes HJ, de Gruijl TD, Walboomers JM, Schiller JT, Dillner J, Helmerhorst TJ, Verheijen RH, Scheper RJ, Meijer CJ: Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia: II. Systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol 1999;80:409-417
8. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 viruslike particle vaccine. J Natl Cancer Inst 2001;93:284-292
9. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA: Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-1919
10. Offringa R, de Jong A, Toes RE, van der Burg SH, Melief CJ: Interplay between human papillomaviruses and dendritic cells. Curr Top Microbiol Immunol 2003;276:215-240
11. McMurray HR, Nguyen D, Westbrook TF, McCance DJ: Biology of human papillomaviruses. Int J Exp Path 2001;82:15-33
12. Melsheimer P, Kaul S, Dobeck S, Bastert G: Immunocytochemical detection of HPV high-risk type L1 capsid proteins in LSIL and HSIL as compared with detection of HPV L1 DNA. Acta Cytol 2003;47:124-128
13. Griesser H, Sander H, Hilfrich R, Moser B, Schenck U: Correlation of immunochemical detection of HPV L1 capsid protein in Pap smears with regression of high-risk HPV positive mild/moderate dysplasia. Anal Quant Cytol Histol 2004;26:241-245
14. Siddiqui MT, Hornaman K, Cohen C, Nassar A: ProEx C immunocytochemistry and high-risk human papillomavirus DNA testing in Papanicolaou tests with atypical squamous cell (ASC-US) cytology: Correlation study with histologic biopsy. Arch Pathol Lab Med 2008;132:1648-1652
15. Melsheimer P: Immunocytochemical detection of human papillomavirus high risk type L1 capsid proteins in LSIL and HSIL as compared with detection of HPV L1 DNA. Acta Cytol 2003;47:124-128
16. Frazer IH: Immunology of papillomavirus infection. Curr Opin Immunol 1996;8:484-491
17. Stern PL, Brown M, Stacey SN, Kitchener HC, Hampson I, Abdel-Hady ES, Moore JV: Natural HPV immunity and vaccination strategies. J Clin Virol 2000;19:57-66
18. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group:: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527
19. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19
20. Roden R, Wu TC: How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006;6:753-763
21. Yoshida T, Sano T, Kanuma T, Owada N, Sakurai S, Fukuda T, Nakajima T: Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions. Cancer 2008;114:83-88
22. Lee H, Lee KJ, Jung CK, Hong JH, Lee YS, Choi YJ, Lee KY, Park G: Expression of HPV L1 capsid protein in cervical specimens with HPV infection. Diagn Cytopathol 2008;36:864-867
23. Hagensee ME, Koutsky LA, Lee SK, Grubert T, Kuypers J, Kiviat NB, Galloway DA: Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions. J Infect Dis 2000;181:1234-1239
24. Stanley M: Immune responses to human papillomavirus. Vaccine (Suppl 1) 2006;24: S16-S22
25. Ostor AG: Natural history of cervical intraepithelial neoplasia: A critical review. Int J Gynecol Pathol 1993;12:1886-1192
26. Negri G, Bellisano G, Zannoni GF, Rivasi F, Kasal A, Vittadello F, Antoniazzi S, Faa G, Ambu R, Egarter-Vigl E: P16ink4a and HPV L1 immunohistochemistry is helpful for estimating the behavior of low-grade dysplastic lesions of the cervix uteri. Am J Surg Pathol 2008;32; 1715-1720